DIAGNOS Inc.

DIAGNOS Inc. is a publicly traded Canadian corporation specializing in the application of Artificial Intelligence (AI) for the early detection of eye-related health issues. Founded in 1998 and headquartered in Brossard, Quebec, the company's mission is to commercialize technologies that combine contextual imaging and data mining to enhance decision-making processes in healthcare.

The company's primary product is Computer Assisted Retina Analysis (CARA), a web-based and cloud-based software platform. CARA assists healthcare professionals in the detection of diabetic retinopathy and age-related macular degeneration (AMD) by analyzing retinal images to identify pathological changes. DIAGNOS also offers consulting services in data analysis and artificial intelligence, serving the healthcare sector across Canada, the United States, Mexico, and other international markets.

DIAGNOS is actively pursuing regulatory approvals for its CARA platform in key global markets. The company has submitted CARA for marketing approval to the Saudi Food and Drug Authority (SFDA) and is targeting submissions to Health Canada and the U.S. Food and Drug Administration (FDA) for 510(k) clearance. André Larente serves as CEO, and Dr. Philippe Couillard chairs the Board of Directors. The platform has been utilized to assess approximately 400,000 patients across 140 clinics in 16 countries.